Current Hepatitis Reports

, Volume 6, Issue 3, pp 114–118

Hepatitis C in correctional institutions

  • Nickolas D. Zaller
  • Lynn E. Taylor
  • Scott Allen
  • Josiah D. Rich


The prevalence of chronic infection with hepatitis C virus (HCV) is estimated to be 17 to 27 times higher among incarcerated individuals than in the general US population. To help stem the epidemic of HCV infection in the United States, correctional institutions and public health systems should be integrated. The incarcerated setting represents the first opportunity for many inmates to access health care. Correctional settings offer an important opportunity to diagnose, prevent, and treat HCV infection. In this article, we review HCV screening, testing, and treatment policies in US correctional institutions and discuss prison responses to the HCV epidemic and the feasibility of treatment within prisons and jails. Finally, we emphasize the importance of links to postrelease medical care for HCV-infected inmates and the necessity of comprehensive strategies to effectively manage HCV infection.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Weinbaum C, Lyerla R, Margolis HS; Centers for Disease Control and Prevention: Prevention and control of infections with hepatitis viruses in correctional settings. Centers for Disease Control and Prevention. MMWR Recomm Rep 2003, 52(RR-1):1–36.PubMedGoogle Scholar
  2. 2.
    Hammett TM, Harmon MP, Rhodes W: The burden of infectious disease among inmates of and releasees from US correctional facilities, 1997. Am J Public Health 2002, 92:1789–1794.PubMedCrossRefGoogle Scholar
  3. 3.
    Harrison PM, Beck AJ: Prisoners in 2004 (Pub. No. NCJ 210677). Washington DC: US Department of Justice; 2005.Google Scholar
  4. 4.
    Mumola C: Substance abuse and treatment, state and federal prisoners, 1997 (Pub. No. NCJ 172871). Washington, DC: US Department of Justice, Office of Justice Programs; 1999.Google Scholar
  5. 5.
    Rogers WB, Seigenthaler CP: Correctional health care as a vital part of community health. J Ambul Care Manage 2001, 24:45–50.PubMedGoogle Scholar
  6. 6.
    Kwiatkowski CF, Corsi KF, Booth RE: The association between knowledge of hepatitis C virus status and risk behaviors among injection drug users. Addiction 2002, 97:1289–1294.PubMedCrossRefGoogle Scholar
  7. 7.
    Brau N, Salvatore M, Rios-Bedova CF, et al.: Slower fibrosis progression in HIV/HCV co-infected patients with successful HV suppression using antiretroviral therapy. J Hepatol 2006, 44:47–55.PubMedCrossRefGoogle Scholar
  8. 8.
    Macalino G, Dhawan D, Rich JD: A missed opportunity: hepatitis C screening of prisoners. Am J Public Health 2005, 95:1739–1740.PubMedCrossRefGoogle Scholar
  9. 9.
    Spaulding AC, Weinbaum CM, Lau DT, et al.: A framework for management of hepatitis C in prisons. Ann Intern Med 2006, 144:762–769.PubMedGoogle Scholar
  10. 10.
    Spaulding A, Greene C, Davidson K, et al.: Hepatitis C in state correctional facilities. Prev Med 1999, 28:92–100.PubMedCrossRefGoogle Scholar
  11. 11.
    Sterling RK, Hifnann CM, Sanyal AJ, et al.: Treatment of chronic hepatitis C virus in the Virginia Department of Corrections: Can compliance overcome racial differences to response? Am J Gastroenterol 2004, 99:866–872.PubMedCrossRefGoogle Scholar
  12. 12.
    Wong JB, McQuillan GM, McHutchison JG, Poynard T: Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000, 90:1562–1569.PubMedCrossRefGoogle Scholar
  13. 13.
    NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002, 19:1–46.Google Scholar
  14. 14.
    Boutwell AE, Allen SA, Rich JD: Opportunities to address the hepatitis C epidemic in the correctional setting. Clin Infect Dis 2005, 40(suppl 5):S367–S372.PubMedCrossRefGoogle Scholar
  15. 15.
    Allen SA, Spaulding AC, Osei AM, et al.: Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med 2003, 138:187–190.PubMedGoogle Scholar
  16. 16.
    Kraus MR, Schafer A, Al-Taie O, Scheurlen M: Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. J Viral Hepat 2005, 12:96–100.PubMedCrossRefGoogle Scholar
  17. 17.
    Hauser P, Khosla J, Aurora H, et al.: A prospective study of the incidence and open-label treatment of interferoninduced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002, 7:942–947.PubMedCrossRefGoogle Scholar
  18. 18.
    Schaefer M, Heinz A, Backmund M: Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules? Addiction 2004, 99:1167–1175.PubMedCrossRefGoogle Scholar
  19. 19.
    Hammet TM: HIV/AIDS and other infectious diseases among correctional inmates: transmission, burden and appropriate response. Am J Public Health 2006, 96:974–978.CrossRefGoogle Scholar
  20. 20.
    Hammet T: Adopting more systematic approaches to hepatitis C treatment in correctional facilities. Ann Intern Med 2003, 138:235–236.Google Scholar
  21. 21.
    Weiss L, Kluger M, McCoy K: Health care accessibility among people that inject drugs or use crack cocaine. New York: Office of Special Populations, New York Academy of Medicine; 2000.Google Scholar
  22. 22.
    Falck-Ytter Y, Kale H, Mullen K, et al.: Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002, 136:288–292.PubMedGoogle Scholar
  23. 23.
    Lauer GM, Walker BD: Hepatitis C virus infection. N Engl J Med 2001, 345:41–52.PubMedCrossRefGoogle Scholar
  24. 24.
    Sherer R: Adherence and antiretroviral therapy in injection drug users. JAMA 1998, 280:567–568.PubMedCrossRefGoogle Scholar
  25. 25.
    Edlin BR, Seal KH, Lorvick J, et al.: Is it justifiable to withhold treatment for hepatitis C from illicit drug users? N Engl J Med 2001, 534:211–215.CrossRefGoogle Scholar
  26. 26.
    Chaisson RE, Barnes GL, Hackman J, et al.: A randomized, controlled trial of interventions to improve adherence to isoniazid therapy to prevent tuberculosis in injection drug users. Am J Med 2001, 110:610–615.PubMedCrossRefGoogle Scholar
  27. 27.
    Rich JD, Macalino GE, McKenzie M, et al.: Syringe prescription to prevent HIV infection in Rhode Island: a case study. Am J Public Health 2001, 91:699–700.PubMedCrossRefGoogle Scholar
  28. 28.
    Dalgard O, Bjoro K, Hellum K, et al.: Treatment of chronic hepatitis C in injecting drug users: 5 years’ follow-up. Eur Addict Res 2002, 8:45–49.PubMedCrossRefGoogle Scholar
  29. 29.
    Asselah T, Vidaud D, Doloy A, et al.: Second infection with a different hepatitis C virus genotype in an intravenous drug user during interferon therapy. Gut 2003, 52:900–902.PubMedCrossRefGoogle Scholar
  30. 30.
    Des Jarlais DC, McKnight C, Friedmann P: Legal syringe purchases by injection drug users, Brooklyn and Queens, New York City, 2000–2001. J Am Pharm Assoc (Wash) 2002, 42:S73–S76.CrossRefGoogle Scholar
  31. 31.
    Management of Hepatitis C. NIH Consens Statement 1997, 15:1–41.Google Scholar
  32. 32.
    Davis GL, Rodrigue JR: Treatment of chronic hepatitis C in active drug users. N Engl J Med 2001, 345:215–217.PubMedCrossRefGoogle Scholar
  33. 33.
    Strader DB: Understudied populations with hepatitis C. Hepatology 2002, 36:S226–S236.PubMedCrossRefGoogle Scholar
  34. 34.
    Backmund M, Meyer K, von Zeilonka M, Eichenlaub D: Treatment of hepatitis C infection in injection drug users. Hepatology 2001, 34:188–193.PubMedCrossRefGoogle Scholar
  35. 35.
    Schaefer M, Schmidt F, Folwaczny C, et al.: Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003, 37:443–451.PubMedCrossRefGoogle Scholar
  36. 36.
    Sylvestre DL: Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend 2002, 67:117–123.PubMedCrossRefGoogle Scholar
  37. 37.
    Hagan H, Des Jarlais DC, Friedman SR, et al.: Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program. Am J Pub Health 1995, 85:1531–1537.CrossRefGoogle Scholar
  38. 38.
    Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998, 47(RR-19):1–39.Google Scholar
  39. 39.
    Pessione F, Ramond MJ, Peters L, et al.: Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking, and abstinence. Liver Int 2003, 23:45–53.PubMedCrossRefGoogle Scholar
  40. 40.
    Harris HE, Ramsay ME, Andrews N, et al.: Clinical course of hepatitis C virus during the first decade of infection: cohort study. BMJ 2002, 324:450–453.PubMedCrossRefGoogle Scholar
  41. 41.
    Jamal MM, Morgan TR: Liver disease in alcohol and hepatitis C. Best Pract Res Clin Gastroenterol 2003, 17:649–662.PubMedCrossRefGoogle Scholar
  42. 42.
    Lubelczyk RAB, Friedmann PD, Lemon SC, et al.: HIV prevention services in correctional drug treatment programs: Do they change risk behaviors? AIDS Educ Prev 2002, 14:117–125.PubMedCrossRefGoogle Scholar
  43. 43.
    Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1999, 48(RR-12):1–37.Google Scholar
  44. 44.
    Lee S, Chan C, Yu M, et al.: Hepatitis B vaccination in patients with chronic hepatitis C. J Med Virol 1999, 59:463–468.PubMedCrossRefGoogle Scholar
  45. 45.
    Vento S, Garofano T, Renzini C, et al.: Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998, 338:286–290.PubMedCrossRefGoogle Scholar
  46. 46.
    Zarski J-P, Bohn B, Bastie A, et al.: Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 1998, 28:27–33.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group, LLC 2007

Authors and Affiliations

  • Nickolas D. Zaller
  • Lynn E. Taylor
  • Scott Allen
  • Josiah D. Rich
    • 1
  1. 1.The Center for Prisoner Health and Human Rights at The Miriam Hospital Immunology CenterProvidenceUSA

Personalised recommendations